Evaluation of the safety of spinosad and milbemycin 5-oxime orally administered to Collies with the MDR1 gene mutation

American Journal of Veterinary Research

Volumn 71, Issue 1, 2010, Pages 115-119

  Sherman, Jeffrey G ^a   Paul, Allan J ^b   Firkins, Lawrence D ^b  

^a ELANCO ANIMAL HEALTH   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARASITIC AGENT; AVERMECTIN; IVERMECTIN; MILBEMYCIN; MILBEMYCIN 5 OXIME; MILBEMYCIN DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN 1; PLACEBO; SPINOSAD; UNCLASSIFIED DRUG;

ARTICLE; ATAXIA; CLINICAL EVALUATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOG; DRUG SAFETY; DRUG SENSITIVITY; GENE MUTATION; HYPERSALIVATION; INTOXICATION; MYDRIASIS; NEUROLOGIC DISEASE; NONHUMAN; SCORING SYSTEM; SINGLE DRUG DOSE; VOMITING;

ANIMALS; ANTHELMINTICS; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; HETEROZYGOTE; HOMOZYGOTE; MACROLIDES; MUTATION; P-GLYCOPROTEIN;

ANIMALIA; CANIS FAMILIARIS;

EID: 75749150897     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.71.1.115     Document Type: Article

References (30)

1. Preston JM. Adverse reactions to unapproved applications (lett). Vet Rec 1983;112:286.
2. Neff MW, Robertson KR, Wong AK, et al. Breed distribution and history of canine mdr1-1Δ, a pharmacogenetic mutation that marks the emergence of breeds from the Collie lineage. Proc Natl Acad Sci U S A 2004;101:11725-11730.
3. Tranquilli WJ, Paul AJ, Todd KS. Assessment of toxicosis induced by high-dose administration of milbemycin oxime in Collies. Am J Vet Res 1991;52:1170-1172.
4. Bayer Animal Health. Companion animal products. Important risk information. Available at: www.bayer-ah.com/products.cfm#. Acessed Sep 21, 2009.
5. Griffin J, Fletcher N, Clemence R, et al. Selamectin is a potent substrate and inhibitor of human and canine P-glycoprotein. J Vet Pharmacol Ther 2005;28:257-265.
6. Pulliam JD, Preston JM. Safety of ivermectin in target animals. In: Campbell WC, ed. Ivermectin and abamectin. New York: Springer-Verlag, 1989;149-161.
7. Paul AJ, Tranquilli WJ, Seward RL, et al. Clinical observations in Collies given ivermectin orally. Am J Vet Res 1987;48:684-685.
8. Nelson OL, Carsten E, Bentjen SA, et al. Ivermectin toxicity in an Australian Shepherd dog with the MDR1 mutation associated with ivermectin sensitivity in Collies. J Vet Intern Med 2003;17:354-356.
9. Mealey KL. Adverse drug reactions in herding breeds. Compend Contin Educ Pract Vet 2006;28:23-33.
10. Lankas GR, Gordon LR. Toxicology. In: Campbell WC, ed. Ivermectin and abamectin. New York: Springer-Verlag, 1989;89-112.
11. Mayer TW, Horton ML. Modulation of monomethylhydrazine-induced seizures by ivermectin. Toxicol Lett 1991;57:167-173.
12. Mealey KL, Bentjen SA, Gay JM, et al. Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 2001;11:727-733.
13. Mealey KL, Northrup NC, Bentjen SA. Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity. J Am Vet Med Assoc 2003;223:1453-1455.
14. Fromm MF. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 2000;38:69-74.
15. Fromm MF, Kim RB, Stein CM, et al. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999;99:552-557.
16. Rodriguez I, Abernethy DR, Woosley RL. P-Glycoprotein in clinical cardiology. Circulation 1999;99:472-474.
17. Dowling P. Pharmacogenetics: it's not just about ivermectin in Collies. Can Vet J 2006;47:1165-1168.
18. Sakaeda T, Nakamura T, Okumura K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull 2002;25:1391-1400.
19. Snyder DE, Meyer J, Zimmermann AG, et al. Preliminary studies on the effectiveness of die novel pulicide, spinosad, for the treatment and control of fleas on dogs. Vet Parasitol 2007;150:345-351.
20. Robertson-Plouch C, Baker KA, Hozak R, et al. Clinical field study of the safety and efficacy of spinosad chewable tablets for controlling fleas on dogs. Vet Ther 2008;9:26-36.
21. Kirst HA, Michel KH, Martin JW, et al. A83543A-D, unique fermentation derived tetracyclic macrolides. Tetrahedron Lett 1991;32:4839-4842.
22. Salgado VL. Studies on the mode of action of spinosad: insect symptoms and physiological correlates. Pestic Biochem Physiol 1998;60:91-102.
23. Sparks TC, Crouse GD, Durst G. Natural products as insecticides: the biology, biochemistry and quantitative structure-activity relationships of spinosyns and spinosoids. Pest Manag Sci 2001;57:896-905.
24. US FDA. Center for Veterinary Medicine Web site. Freedom of Information Summary. Comfortis. Available at: www.fda.gov/cvm/FOl/141-277o092507.pdf. Accessed Mar 9,2008.
25. Comfortis™ (spinosad) chewable tablets. Available at: www.comfortis4dogs.com/-layouts/downloads/comfortis-product-labeLpdf. Accessed Mar 9, 2008.
26. Veterinary International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Medicinal Products (VICH). (Target animal safety) - pharmaceuticals. VICH GL 43. Brussels: VICH, 1998.
27. National Research Council. Guide for the care and use of laboratory animals. Washington, DC: National Academy Press, 1996.
28. Fassler PE, Tranquilli WJ, Paul AJ, et al. Evaluation of the safety of ivermectin administered in a beef-based formulation to ivermectin-sensitive Collies. J Am Vet Med Assoc 1991;199:457-460.
29. Paul AJ, Hutchens DE, Firkins LD, et al. Effects of dermal application of 10.0% imidacloprid-0.08% ivermectin in ivermectin-sensitive Collies. Am J Vet Res 2004;65:277-278.
30. US FDA Center for Veterinary Medicine. COMFORTIS® and ivermectin interaction safety warning notification. Available at: www.fda.gov/ AnimalVeterinary/NewsEvents/CVMUpdates/ucm047942.htm. Accessed Nov 11, 2008.